TY - JOUR
T1 - Aspergillosis complicating severe coronavirus disease
AU - Marr, Kieren A.
AU - Platt, Andrew
AU - Tornheim, Jeffrey A.
AU - Zhang, Sean X.
AU - Datta, Kausik
AU - Cardozo, Celia
AU - Garcia-Vidal, Carolina
N1 - Funding Information:
K.A.M. has received consultative income from Amplyx, Cidara, Merck, and Sfunga; licensing royalties from MycoMed Technologies; and research grant from Merck. C.G.-V. has received honoraria from Gilead Science, Merck, Novartis, Pfizer, Jannsen, and Lilly; and research grants from Gilead and Merck.
Funding Information:
Creation of Figure 3 was supported by Cidara Therapeutics.
Publisher Copyright:
© 2021 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Aspergillosis complicating severe influenza infection has been increasingly detected worldwide. Recently, coronavirus disease-associated pulmonary aspergillosis (CAPA) has been detected through rapid reports, primarily from centers in Europe. We provide a case series of CAPA, adding 20 cases to the literature, with review of pathophysiology, diagnosis, and outcomes. The syndromes of pulmonary aspergillosis complicating severe viral infections are distinct from classic invasive aspergillosis, which is recognized most frequently in persons with neutropenia and in other immunocompromised persons. Combined with severe viral infection, aspergillosis comprises a constellation of airway-invasive and angio-invasive disease and results in risks associated with poor airway fungus clearance and killing, including virus- or inflammation-associated epithelial damage, systemic immunosuppression, and underlying lung disease. Radiologic abnormalities can vary, reflecting different pathologies. Prospective studies reporting poor outcomes in CAPA patients underscore the urgent need for strategies to improve diagnosis, prevention, and therapy.
AB - Aspergillosis complicating severe influenza infection has been increasingly detected worldwide. Recently, coronavirus disease-associated pulmonary aspergillosis (CAPA) has been detected through rapid reports, primarily from centers in Europe. We provide a case series of CAPA, adding 20 cases to the literature, with review of pathophysiology, diagnosis, and outcomes. The syndromes of pulmonary aspergillosis complicating severe viral infections are distinct from classic invasive aspergillosis, which is recognized most frequently in persons with neutropenia and in other immunocompromised persons. Combined with severe viral infection, aspergillosis comprises a constellation of airway-invasive and angio-invasive disease and results in risks associated with poor airway fungus clearance and killing, including virus- or inflammation-associated epithelial damage, systemic immunosuppression, and underlying lung disease. Radiologic abnormalities can vary, reflecting different pathologies. Prospective studies reporting poor outcomes in CAPA patients underscore the urgent need for strategies to improve diagnosis, prevention, and therapy.
UR - http://www.scopus.com/inward/record.url?scp=85098593728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098593728&partnerID=8YFLogxK
U2 - 10.3201/eid2701.202896
DO - 10.3201/eid2701.202896
M3 - Article
C2 - 33084566
AN - SCOPUS:85098593728
SN - 1080-6040
VL - 27
SP - 18
EP - 25
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 1
ER -